Shares of Lexicon Pharmaceuticals (LXRX) have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk (NVO) last week.Per the deal terms, Lexicon will complete certain preclinical activities before Novo Nordisk takes over the development, manufacturing and commercialization of LX9851. NVO will also be responsible for LX9851’s investigational new drug (IND) filing.In return, LXRX is eligible to receive $75 million as an upfront payment from NVO. Inclu ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mis ...

Fourth Quarter and Full Year 2024 Earnings Presentation March 2025 1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadi ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operat ...

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.18%. A quarter ago, it was expected that this drugmaker would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company ha ...

Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET The Woodlands, Texas, March 6, 2025 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for th ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate milestones and acc ...